Abstract
Central nervous system is not spared from the deleterious effects of diabetes, since several studies have described neuropsychological and neurobehavioral changes in diabetic subjects, suggesting that diabetic encephalopathy should be recognized as a complication of this complex metabolic disorder. In fact, psychiatric manifestations may accompany this encephalopathy, since the prevalence of depression in diabetic patients is much higher than in the general population. Furthermore, evidences from preclinical and clinical studies suggest that GABA plays a role both in the pathophysiology of the diabetic encephalopathy-related depression. So, this review addresses the GABAergic modulation in diabetic encephalopathy-related depression. Data presented from literature support the association between GABA and depressive- like behaviors in diabetic encephalopathy, being this neurotransmitter a potential target for the treatment of diabetes, depression and related comorbidities.
Keywords: Diabetes, depression, oxidative stress, GABA, clonazepam, insulin, pancreas.
Current Pharmaceutical Design
Title:GABAergic Modulation in Diabetic Encephalopathy-Related Depression
Volume: 21 Issue: 34
Author(s): Carlos Alberto Yasin Wayhs, Helena Maria Tannhauser Barros and Carmen Regla Vargas
Affiliation:
Keywords: Diabetes, depression, oxidative stress, GABA, clonazepam, insulin, pancreas.
Abstract: Central nervous system is not spared from the deleterious effects of diabetes, since several studies have described neuropsychological and neurobehavioral changes in diabetic subjects, suggesting that diabetic encephalopathy should be recognized as a complication of this complex metabolic disorder. In fact, psychiatric manifestations may accompany this encephalopathy, since the prevalence of depression in diabetic patients is much higher than in the general population. Furthermore, evidences from preclinical and clinical studies suggest that GABA plays a role both in the pathophysiology of the diabetic encephalopathy-related depression. So, this review addresses the GABAergic modulation in diabetic encephalopathy-related depression. Data presented from literature support the association between GABA and depressive- like behaviors in diabetic encephalopathy, being this neurotransmitter a potential target for the treatment of diabetes, depression and related comorbidities.
Export Options
About this article
Cite this article as:
Wayhs Alberto Yasin Carlos, Barros Maria Tannhauser Helena and Vargas Regla Carmen, GABAergic Modulation in Diabetic Encephalopathy-Related Depression, Current Pharmaceutical Design 2015; 21 (34) . https://dx.doi.org/10.2174/1381612821666150914121331
DOI https://dx.doi.org/10.2174/1381612821666150914121331 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Mitochondrial Oxidative Stress Through Lipoic Acid Synthase: A Novel Strategy to Manage Diabetic Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of Inflammation in Epilepsy
Current Pediatric Reviews Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis
Current Pharmaceutical Design Biological Activities of Quinoline Derivatives
Mini-Reviews in Medicinal Chemistry CRISPR/Cas9 in Stem Cell Research: Current Application and Future Perspective
Current Stem Cell Research & Therapy Editorial: Perioperative Pharmacological Management: From Prescription Medications to Dietary Supplements
Current Clinical Pharmacology Aspartate and Glutamate Mimetic Structures in Biologically Active Compounds
Current Medicinal Chemistry Connexins as Precocious Markers and Molecular Targets for Chemical and Pharmacological Agents in Carcinogenesis
Current Medicinal Chemistry Machine Learning Approaches for Cognitive State Classification and Brain Activity Prediction: A Survey
Current Bioinformatics Evaluation of Specific Antibody Responses in Patients with Selective IgA Deficiency and Ataxia Telangiectasia
Endocrine, Metabolic & Immune Disorders - Drug Targets Trends in Utilization of the Pharmacological Potential of Chalcones
Current Clinical Pharmacology Investigating Serotonergic Function Using Positron Emission Tomography: Overview and Recent Findings
Current Pharmaceutical Design Targeting of Low-Molecular Weight Drugs to Mammalian Mitochondria
Drug Design Reviews - Online (Discontinued) Regeneration in a Degenerating Brain: Potential of Allopregnanolone as a Neuroregenerative Agent
Current Alzheimer Research Prader-Willi Syndrome: Genetics, Phenotype, and Management
Current Psychiatry Reviews GABAA Receptor Specific Pyrazolopyrimidines as Potential Imaging Agents: In Vivo Characteristics of a New 18F-labelled Indiplon Derivative
Current Radiopharmaceuticals Conference Report: 10th International Summer School of Neurology: Celebrating a Decade of Success: 5th July, 2015 – 9th July, 2015 | Eforie Nord, Romania
CNS & Neurological Disorders - Drug Targets Nitric Oxide and Teratogenesis: An Update
Current Pharmaceutical Design Recent Advances and Patents on Nanoscale Systems and Triggerable Drug Delivery in Medical Devices
Recent Patents on Biomedical Engineering (Discontinued) Adult Neurogenic and Antidepressant Effects of Adiponectin: A Potential Replacement for Exercise
CNS & Neurological Disorders - Drug Targets